Stereotaxis Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw accelerating adoption of new robotic and digital products, with recurring revenue up 270% sequentially and robust physician feedback. Supply constraints limit catheter revenue growth, but guidance anticipates strong recurring and system revenue in the second half, with cash flow profitability targeted for early 2027.
-
Q1 2026 saw revenue decline due to transition from legacy products, but regulatory approvals and new product launches signal a foundational shift. Strong demand for new catheters and digital systems, plus the Robocath acquisition, support double-digit revenue growth guidance for 2026.
-
The acquisition of Robocath brings complementary robotic technology, accelerating the strategy to lead in endovascular procedures. The deal includes up to $45 million in payments, targets a $20–30 billion market, and expects break-even by year three post-close.
Fiscal Year 2025
-
Delivered 36% Q4 revenue growth and launched new robotic and catheter products after key regulatory approvals. Manufacturing ramp and transition to proprietary catheters are underway, with double-digit revenue growth and margin expansion expected in 2026.
-
Q2 2025 revenue nearly doubled year-over-year, driven by new product launches and regulatory milestones. MAGIC and MAGIC Sweep catheters are expanding recurring revenue, with guidance reaffirmed for double-digit growth and a strengthened cash position post-equity raise.
-
Q1 2025 saw 9% revenue growth, driven by strong recurring revenue from proprietary catheters and initial MAGIC sales in Europe. Guidance for double-digit growth in 2025 was reiterated, with key regulatory milestones expected to unlock further upside.
Fiscal Year 2024
-
Achieved strong Q4 revenue growth and key regulatory milestones, including FDA submissions for new catheters and the GenesisX robot. 2025 guidance is conservative, with flat system revenue and sequential recurring revenue growth, while strategic expansion and product launches set the stage for substantial growth in 2026.
-
Q3 2024 saw 18% revenue growth, driven by Genesis system sales and APT integration, with strong momentum in Europe and a robust product pipeline. Regulatory progress continues for MAGiC and Genesis X, while recurring revenue is set to grow further.
-
Q2 revenue declined due to delayed system deliveries, but a strong rebound is expected in the second half with new GenesisX and MAGiC launches pending regulatory approval. The APT acquisition is already boosting catheter sales, and the company anticipates ending 2024 with $13M cash and no debt.